drugset / Trial / NCT01578330

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

NCT01578330

Phase 4 Completed 42 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelSupportive care

Summary

The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.

Timeline

Start
2012-10
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fingolimod Small molecule 0.5 mg Oral